Patents by Inventor Donald Weaver
Donald Weaver has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11931480Abstract: A hydrogel material for modulating an immune response in a human subject or other mammal includes a collection of microgel particles having one or more network cross linker components, wherein the microgel particles, when exposed to an endogenous or exogenous annealing agent, links the microgel particles together in situ to form a covalently-stabilized scaffold of microgel particles having interstitial spaces formed between the microgel particles and wherein the collection of microgel particles further includes at least one of an antigen and an adjuvant.Type: GrantFiled: February 14, 2017Date of Patent: March 19, 2024Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Dino Di Carlo, Westbrook Weaver, Tatiana Segura, Philip Scumpia, Donald R. Griffin
-
Patent number: 11931481Abstract: A hydrogel material for use in a human subject or other mammal includes a collection of microgel particles having one or more network cross linker components, wherein the microgel particles, when exposed to an endogenous or exogenous annealing agent, links the microgel particles together in situ to form a covalently-stabilized scaffold of microgel particles having pores formed between the microgel particles wherein the pores are substantially devoid of hydrogel.Type: GrantFiled: July 30, 2022Date of Patent: March 19, 2024Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Dino Di Carlo, Westbrook Weaver, Tatiana Segura, Jaekyung Koh, Philip Scumpia, Donald R. Griffin
-
Publication number: 20230265079Abstract: Inhibition of indoleamine 2,3-dioxygenase (IDO1) is an attractive immunotherapeutic approach for the treatment of a variety of cancers. Dysregulation of this enzyme has also been implicated in other severe diseases such as Alzheimer's disease and arthritis. Small molecule inhibitors of IDO, syntheses, and uses thereof are provided.Type: ApplicationFiled: January 12, 2023Publication date: August 24, 2023Inventors: Donald WEAVER, Michael G. BRANT, Stephanie WOHNIG, Fan WU, Jake GOODWIN-TINDALL, Autumn MEEK, Paolo SCHIAVINI
-
Patent number: 11572354Abstract: Inhibition of indoleamine 2,3-dioxygenase (IDO1) is an attractive immunotherapeutic approach for the treatment of a variety of cancers. Dysregulation of this enzyme has also been implicated in other severe diseases such as Alzheimer's disease and arthritis. Small molecule inhibitors of Formula (Ia) and (Ib) of IDO, their synthesis, and uses thereof are provided.Type: GrantFiled: January 9, 2019Date of Patent: February 7, 2023Assignee: University Health NetworkInventors: Donald Weaver, Michael G. Brant, Stephanie Wohnig, Fan Wu, Jake Goodwin-Tindall, Autumn Meek, Paolo Schiavini
-
Publication number: 20210053942Abstract: Inhibition of indoleamine 2,3-dioxygenase (IDO1) is an attractive immunotherapeutic approach for the treatment of a variety of cancers. Dysregulation of this enzyme has also been implicated in other severe diseases such as Alzheimer's disease and arthritis. Small molecule inhibitors of Formula (Ia) and (Ib) of IDO, their synthesis, and uses thereof are provided.Type: ApplicationFiled: January 9, 2019Publication date: February 25, 2021Inventors: Donald WEAVER, Michael G. BRANT, Stephanie WOHNIG, Fan WU, Jake GOODWIN-TINDALL, Autumn MEEK, Paulo SCHIAVINI
-
Patent number: 8835476Abstract: The synthesis and activity of novel LpxA inhibitors is described, these inhibitors present antibacterial activity. The compounds were designed based on a receptor model developed using the crystal structure of LpxA and are arranged to have a favorable binding interaction at the active site of the enzyme. In particular, the compounds present the following formula (I) where V, W, X, Y and Z can be independently C, S, N or O and P1, P2 and P3 are ligands to bind to the three points of the proposed pharmacophore model. They can be chosen from a variety of groups.Type: GrantFiled: March 6, 2006Date of Patent: September 16, 2014Inventors: Fan Wu, Donald Weaver, Chris Barden, Christopher McMaster, David Byers, Annette Henneberry, Fuqiang Ban
-
Publication number: 20130267571Abstract: The present application provides a terpene analogue of Formula (I) or a pharmaceutically acceptable isomer, salt or ester thereof, and methods and uses thereof for treating neurological conditions such as pain in general and neuropathic pain. These terpene analogues can also be used to treat other electrical disorders in the central and peripheral nervous system. Also provided are methods of synthesizing the terpene analogues of Formula I.Type: ApplicationFiled: September 14, 2011Publication date: October 10, 2013Applicant: NeuroQuest Inc.Inventors: Mark A. Reed, Donald Weaver, Shengguo Sun, Alexander McLellan, Erhu Lu
-
Publication number: 20110281951Abstract: Therapeutic compounds and methods for modulating amyloid aggregation in a subject, whatever its clinical setting, are described. Amyloid aggregation is modulated by the administration to a subject of an effective amount of a therapeutic compound of the formula or a pharmaceutically acceptable salt or ester, such that modulation of amyloid aggregation occurs. R1 and R2 are each independently a hydrogen atom or a substituted or unsubstituted aliphatic or aryl group. Z and Q are each independently a carbonyl (C?O), thiocarbonyl (C?S), sulfonyl (SO2), or sulfoxide (S?O) group. “k” and “m” are 0 or 1, provided when k is 1, R1 is not a hydrogen atom, and when m is 1, R2 is not a hydrogen atom. In an embodiment, at least one of k or m must equal 1. “p” and “s” are each independently positive integers selected such that the biodistribution of the therapeutic compound for an intended target site is not prevented while maintaining activity of the therapeutic compound.Type: ApplicationFiled: April 14, 2011Publication date: November 17, 2011Inventors: Walter Szarek, Donald Weaver, Xianqi Kong, Heather Gordon
-
Publication number: 20110002875Abstract: Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.Type: ApplicationFiled: June 8, 2010Publication date: January 6, 2011Applicant: Bellus Health (International) LimitedInventors: Robert Kisilevsky, Walter Szarek, Donald Weaver
-
Publication number: 20100137388Abstract: The present invention provides for therapies characterized in part by co-administration or combination of antibiotic agents with medicinal compositions comprising as the pro-antibiotic active ingredient either a compound represented by a formula [I] or a pharmaceutically acceptable composite thereof; [wherein X represents oxygen, sulfur, NH, or N-alkyl; R1 and R2 represent hydrogen, tetrazole, or alkyltetrazole, respectively (with the restriction that if R1 is not hydrogen, R2 must be, and vice versa); R3 represents e.g., benzyl, phenyl optionally substituted, biphenyl, napthyl, N-phenylcarboxamido, etc., R4 represents e.g. carboxylic acid, or its alkyl esters, or a bioisoteric equivalent thereof, etc.; R5 represents e.g. hydrogen, carboxylic acid, etc.] in particular, medicine which is useful as therapeutic and/or protective drugs for infectious and/or inflammatory diseases. Other relevant compounds are also provided.Type: ApplicationFiled: April 16, 2008Publication date: June 3, 2010Inventors: Christopher J. Barden, Annette L. Henneberry, David M. Byers, Christopher R. McMaster, Donald Weaver, Fan Wu
-
Publication number: 20100076028Abstract: The synthesis and activity of novel LpxA inhibitors is described, these inhibitors present antibacterial activity. The compounds were designed based on a receptor model developed using the crystal structure of LpxA and are arranged to have a favorable binding interaction at the active site of the enzyme. In particular, the compounds present the following formula (I) where V, W, X, Y and Z can be independently C, S, N or O and P1, P2 and P3 are ligands to bind to the three points of the proposed pharmacophore model. They can be chosen from a variety of groups.Type: ApplicationFiled: March 6, 2006Publication date: March 25, 2010Inventors: Fan Wu, Donald Weaver, Chris Barden, Christopher McMaster, David Byers, Annette Henneberry, Fuqiang Ban
-
Publication number: 20090099100Abstract: Therapeutic compounds and methods for modulating amyloid aggregation in a subject, whatever its clinical setting, are described. Amyloid aggregation is modulated by the administration to a subject of an effective amount of a therapeutic compound of the formula or a pharmaceutically acceptable salt or ester, such that modulation of amyloid aggregation occurs. R1 and R2 are each independently a hydrogen atom or a substituted or unsubstituted aliphatic or aryl group. Z and Q are each independently a carbonyl (C?O), thiocarbonyl (C?S), sulfonyl (SO2), or sulfoxide (S?O) group. “k” and “m” are 0 or 1, provided when k is 1, R1 is not a hydrogen atom, and when m is 1, R2 is not a hydrogen atom. In an embodiment, at least one of k or m must equal 1. “p” and “s” are each independently positive integers selected such that the biodistribution of the therapeutic compound for an intended target site is not prevented while maintaining activity of the therapeutic compound.Type: ApplicationFiled: July 7, 2008Publication date: April 16, 2009Applicant: Bellus Health (International) LimitedInventors: Walter Szarek, Donald Weaver, Xianqi Kong, Heather Gordon
-
Publication number: 20070265334Abstract: Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.Type: ApplicationFiled: February 16, 2007Publication date: November 15, 2007Applicant: Neurochem (International) LimitedInventors: Robert Kisilevsky, Walter Szarek, Donald Weaver
-
Publication number: 20070078137Abstract: The present invention relates to compositions which inhibit the binding of nerve growth factor to the p75NTR common neurotrophin receptor and methods of use thereof. In one embodiment, the compound which inhibits binding of nerve growth factor to p75NTR comprises, particularly when bound to nerve growth factor, at least two of the following: (1) a first electronegative atom or functional group positioned to interact with Lys34 of nerve growth factor; (2) a second electronegative atom or functional group positioned to interact with Lys95 of nerve growth factor; (3) a third electronegative atom or functional group positioned to interact with Lys88 of nerve growth factor; (4) a fourth electronegative atom or functional group positioned to interact with Lys32 of nerve growth factor; and (5) a hydrophobic moiety which interacts with the hydrophobic region formed by Ile31, Phe101 and Phe86 of nerve growth factor.Type: ApplicationFiled: September 25, 2006Publication date: April 5, 2007Inventors: Gregory Ross, Igor Shamovsky, Sandra Marone, Donald Weaver, Richard Riopelle
-
Publication number: 20070060606Abstract: Novel compounds that modulate PDE10A, a gene that is primarily expressed in medium spiny neurons of the mammalian striatum and has been found to inhibit striatal output by reducing spiny medium excitability and effect cAMP and cGMP signalling cascades in vivo in rats, and methods for treating psychosis and schizophrenia using the novel compounds. Methods for screening for further compounds to modulate PDE10A activity are also taught.Type: ApplicationFiled: August 23, 2006Publication date: March 15, 2007Inventors: Harold Robertson, Eileen Denovan-Wright, Donald Weaver
-
Publication number: 20070042497Abstract: The present invention exploits the discovery that amounts of uracil and thymine metabolites, especially ?-aminoisobutyric acid, in various bodily fluids, especially urine, are correlated with the occurrence of epilepsy when compared to matched control subjects. Analytical and diagnostic protocols, including a novel high performance liquid chromatography system, for use in the invention are disclosed.Type: ApplicationFiled: October 26, 2006Publication date: February 22, 2007Applicant: Queens University at KingstonInventors: Allyson Campbell, Donald Weaver, Angela Lyon, John Carran
-
Publication number: 20070015813Abstract: In certain embodiments, the invention is directed to a method for treating a protein folding disorder comprising administering to a subject a compound of the formulas disclosed. In preferred embodiments, the compounds are bis-indole compounds.Type: ApplicationFiled: May 30, 2006Publication date: January 18, 2007Applicant: QUEEN'S UNIVERSITY AT KINGSTONInventors: Michael Carter, Mark Hadden, Donald Weaver, Sheila Jacobo, Erhu Lu
-
Publication number: 20060167095Abstract: Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.Type: ApplicationFiled: December 22, 2005Publication date: July 27, 2006Inventors: Robert Kisilevsky, Walter Szarek, Donald Weaver
-
Publication number: 20060063793Abstract: The present invention relates to compositions which inhibit the binding of nerve growth factor to the p75NTR common neurotrophin receptor and methods of use thereof. In one embodiment, the compound which inhibits binding of nerve growth factor to p75NTR comprises, particularly when bound to nerve growth factor, at least two of the following: (1) a first electronegative atom or functional group positioned to interact with Lys34 of nerve growth factor; (2) a second electronegative atom or functional group positioned to interact with Lys95 of nerve growth factor; (3) a third electronegative atom or functional group positioned to interact with Lys88 of nerve growth factor; (4) a fourth electronegative atom or functional group positioned to interact with Lys32 of nerve growth factor; and (5) a hydrophobic moiety which interacts with the hydrophobic region formed by Ile31, Phe101 and Phe86 of nerve growth factor.Type: ApplicationFiled: November 7, 2005Publication date: March 23, 2006Inventors: Gregory Ross, Igor Shamovsky, Sandra Marone, Donald Weaver, Richard Riopelle
-
Publication number: 20060014752Abstract: Methods and compounds, such as ?-heterocyclic-?-amino acids, useful for the inhibition of epileptogenesis are disclosed. Methods for preparing and using the ?-heterocyclic-?-amino acids of the invention are also described.Type: ApplicationFiled: April 4, 2005Publication date: January 19, 2006Applicant: Queen's University at KingstonInventors: Donald Weaver, Allyson Campbell